Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy: a prospective study
ZHU Deng-Na1, WANG Ming-Mei1, WANG Jun1, ZHANG Wei1, LI He-Zhou2, YANG Po2, XIONG Hua-Chun1, NIU Guo-Hui1, LI San-Song1, ZHAO Yun-Xia1
Department of Children's Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract：Objective To investigate the long-term clinical efficacy and adverse effects of botulinum toxin-A(BTX-A) injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy.Methods Eighty children aged 9-36 months with cerebral palsy and gastrocnemius spasticity were selected and randomly divided into a BTX-A injection group and a conventional treatment group(n=40 each).The children in the BTX-A injection group received injections of BTX-A guided by color Doppler ultrasound and 4 courses of rehabilitation training after injection.Those in the conventional treatment group received 4 courses of the same rehabilitation training alone.Before treatment and at 1, 2, 3, and 6 months after treatment, the modified Tardieu scale(MTS) was applied to assess the degree of gastrocnemius spasticity, the values in the passive state measured by surface electromyography(sEMG) were applied to evaluate muscle tension, and the Gross Motor Function Measure(GMFM) was used to evaluate gross motor function.Results Compared with the conventional treatment group, the BTX-A injection group had significantly greater reductions in MTS score and the values in the passive state measured by sEMG(PPConclusions BTX-A injection is effective and safe in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy.
ZHU Deng-Na,WANG Ming-Mei,WANG Jun et al. Effect of botulinum toxin A injection in the treatment of gastrocnemius spasticity in children aged 9-36 months with cerebral palsy: a prospective study[J]. CJCP, 2016, 18(2): 123-129.
Koman LA, Mooney JF 3rd, Smith B, et al. Management of cerebral palsy with botulinum-A toxin:preliminary investigation[J]. J Pediatr Orthop, 1993, 13(4):489-495.
[2]
Intiso D. Therapeutic use of botulinum toxin in neurorehabilitation[J]. J Toxicol, 2012, 2012:Article ID 802893, 12 pages.
[3]
Druschel C, Althuizes HC, Funk JF, et al. Off label use of botulinum toxin in children under two years of age:a systematic review[J]. Toxins, 2013, 5(1):60-72.
[4]
Tedroff K, Lowing K, Haglund-Akerlind Y, et al. Botulinum toxin A treatment in toddlers with cerebral palsy[J]. Acta Paediatr, 2010, 99(8):1156-1162.
Abolhasani H, Ansari NN, Naghdi S, et al. Comparing the validity of the Modified Modified Ashworth Scale(MMAS) and the Modified Tardieu Scale(MTS) in the assessment of wrist flexor spasticity in patients with stroke:protocol for a neurophysiological study[J]. BMJ Open, 2012, 2(6):e001394.
[7]
Olesch CA, Greaves S, Imms C, et al. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia:a randomized controlled trial[J]. Dev Med Child Neurol, 2010, 52(1):79-86.
[8]
Graham HK, Boyd R, Carlin JB, et al. Does botulinum toxin a combined with bracing prevent hip displacement in children with cerebral palsy and "hips at risk"? A randomized, controlled trial[J]. J Bone Joint Surg Am, 2008, 90(1):23-33.
[9]
Zonta MB, Bruck I, Puppi M, et al. Effects of early spasticity treatment on children with hemiplegic cerebral palsy:a preliminary study[J]. Arq Neuropsiquiatr, 2013, 71(7):453-461.
[10]
Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy[J]. Eur J Paediatr Neurol, 2010, 14(1):45-66.
[11]
Fosang AL, Galea MP, McCoy AT, et al. Measures of muscle and joint performance in the lower limb of children with cerebral palsy[J]. Dev Med Child Neurol, 2003, 45(10):664-670.
[12]
Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity[J]. Disabil Rehabil, 2006, 28(15):899-907.
[13]
Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it[J]. Clin Rehabil, 2006, 20(2):173-182.
[14]
Gracies JM, Burke K, Clegg NJ, et al. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy[J]. Arch Phys Med Rehabil, 2010, 91(3):421-428.
[15]
Bar-On L, Aertbeliën E, Molenaers G, et al. Instrumented assessment of the effect of Botulinum Toxin-A in the medial hamstrings in children with cerebral palsy[J]. Gait Posture, 2014, 39(1):17-22.
[16]
van den Noort JC, Scholtes VA, Becher JG, et al. Evaluation of the catch in spasticity assessment in children with cerebral palsy[J]. Arch Phys Med Rehabil, 2010, 91(4):615-623.
Thomas RE, Johnston LM, Boyd RN, et al. GRIN:"GRoup versus INdividual physiotherapy following lower limb intramuscular Botulinum Toxin-A injections for ambulant children with cerebral palsy:an assessor-masked randomised comparison trial":study protocol[J]. BMC Pediatr, 2014, 14:35.
[19]
Colovic H, Dimitrijevic L, Stankovic I, et al. The effects of botulinum toxin type A on improvement and dynamic spastic equinus correction in children with cerebral palsy-preliminary results[J]. Arch Med Sci, 2014, 10(5):979-984.
